About Inventiva S.A. - American Depository Shares (IVA)
Inventiva S.A. is a biopharmaceutical company that focuses on developing innovative therapies for the treatment of metabolic and fibrotic diseases, particularly those related to liver health. The company employs a range of drug discovery and development strategies, including small molecules and biologics, to address unmet medical needs in these areas. Through its research and clinical programs, Inventiva aims to bring forward novel treatments that improve patient outcomes and enhance quality of life, leveraging its expertise in molecular biology and drug development. Read More
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.
Companies Reporting Before The Bell • Inventiva (NASDAQ: IVA) is projected to report quarterly loss at $0.41 per share on revenue of $5.31 million. • Uxin (NASDAQ: UXIN) is estimated to report earnings for its second quarter.
Inventiva (NASDAQ: IVA) is gearing up to announce its quarterly earnings on Monday, 2025-09-29. Here's a quick overview of what investors should know before the release. Analysts are estimating that Inventiva will report an earnings per share (EPS) of $-0.41.
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the “Greed” zone on Thursday. U.S. stocks settled lower on Thursday, with the Nasdaq Composite falling more than 100 points during the session. The S&P 500 fell for the third session in a row.
Inventiva (NASDAQ: IVA) is set to give its latest quarterly earnings report on Friday, 2025-09-26. Here's what investors need to know before the announcement. Analysts estimate that Inventiva will report an earnings per share (EPS) of $-0.41.
